Your session is about to expire
← Back to Search
BMS-986326 for Lupus
Study Summary
This trial tests the safety, levels, and effects of BMS-986326, given via IV or SC, for different types of lupus.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this experimental research open to adults aged 20 and up?
"This clinical investigation abides by the regulation that candidates need to be between 18 and 75 years of age in order to participate."
How secure is the application of BMS-986326 Dose 1 IV in Cohort A?
"According to our internal assessment, Cohort A: BMS-986326 Dose 1 IV has limited evidence backing its safety and efficacy. Therefore, it was given a score of 1 on the scale from 1 to 3."
Is it possible to become a participant of this clinical experiment?
"This trial, which has a recruitment goal of 60 patients, is limited to those suffering from lupus and who are aged between 18 and 75."
Where are the participating sites for this clinical trial?
"The current trial is being conducted in numerous locations, including North Georgia Rheumatology in Lawrenceville (GA), IMA Clinical Research Las Vegas (NV), and Allen Arthritis located in Allen (TX). A total of 11 sites are participating."
Is enrollment for this trial currently available to participants?
"The information listed on clinicaltrials.gov indicates that this trial has ceased recruiting participants, with the first posting taking place in September 15th, 2023 and its most recent update occurring August 23rd of the same year. Despite this study no longer seeking candidates there are 6 other trials searching for patients currently."
Share this study with friends
Copy Link
Messenger